Wed, July 25, 2012
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ] - Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012
Fri, July 6, 2012
Thu, July 5, 2012
Wed, July 4, 2012
[ Wed, Jul 04th 2012 ] - Market Wire
Warnex Announces Refinancing
Tue, July 3, 2012
Mon, July 2, 2012
Sun, July 1, 2012
Fri, June 29, 2012

Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012


//health-fitness.news-articles.net/content/2012/ .. conference-call-and-webcast-on-july-25-2012.html
Published in Health and Fitness on Wednesday, July 11th 2012 at 6:38 GMT by Market Wire   Print publication without navigation


Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host... -- TARRYTOWN, N.Y., July 11, 2012 /PRNewswire/ --

Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012

TARRYTOWN, N.Y., July 11, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its second quarter 2012 financial and operating results on Wednesday, July 25, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EDT that day.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at [ www.regeneron.com ].  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, EYLEA® (aflibercept) Injection and ARCALYST® (rilonacept) Injection for Subcutaneous Use.  Regeneron has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for EYLEA and ARCALYST and for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].

Contact Information:

Manisha Narasimhan, Ph.D. 

Peter Dworkin

Investor Relations                    

Corporate Communications                               

914-847-5126                          

914.847.7640                

[ Manisha.narasimhan@regeneron.com ]          

[ peter.dworkin@regeneron.com ]

SOURCE Regeneron Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.regeneron.com ]


Publication Contributing Sources